Literature DB >> 8768358

Case study: neuroleptic malignant syndrome without pyrexia.

A F Hynes1, E L Vickar.   

Abstract

Fever is generally considered to be an essential feature of neuroleptic malignant syndrome (NMS). The authors present the case of a 12-year-old boy who had many features of NMS but did not have fever. This case emphasizes the importance of assessing the total clinical situation. It also supports the concept of neuroleptic-induced catatonia (NIC) and NMS as disorders on the same spectrum. A scoring system is offered as a guide to severity of NIC-NMS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768358     DOI: 10.1097/00004583-199607000-00024

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  6 in total

1.  Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report.

Authors:  Daniel Molina; Leslie E Tingle; Xiaohui Lu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

3.  Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea.

Authors:  U Patel; M Agrawal; P Krishnan; S Niranjan
Journal:  J Natl Med Assoc       Date:  2002-04       Impact factor: 1.798

4.  Atypical neuroleptic malignant syndrome.

Authors:  Ann Collins; Drew Davies; Sharmila Menon
Journal:  BMJ Case Rep       Date:  2016-06-13

5.  Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam.

Authors:  Adeeb Yacoub; Andrew Francis
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

6.  Probable case of neuroleptic malignant syndrome following administration of antituberculotic drugs in a chlorpromazine-treated patient.

Authors:  GeumSook Shim; Do-Hyung Kang; Jun Soo Kwon
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.